MassBio CEO & President Kendalle Burlin O’Connell originally posted this update to LinkedIn.
Congress heads into recess without a Senate vote-a-rama we’d been tracking. The Senate is now expected to resume work on the bill the week of June 1, and we’ll be watching closely for MFN-style amendments when they do. In the meantime, here’s what else we’ve been watching this week:
Bhattacharya Defends FY27 NIH Budget Request Before Senate Appropriators: NIH Director Jay Bhattacharya is testifying before the Senate Appropriations Subcommittee on Labor, HHS, Education, and Related Agencies to defend the President’s FY27 budget request of $41.5 billion for NIH today. The $41.5 billion figure represents roughly a 12% cut from the FY26 enacted level of $47.2 billion, and the proposal would eliminate three institutes outright: the National Institute on Minority Health and Health Disparities, the Fogarty International Center, and the National Center for Complementary and Integrative Health. Bhattacharya’s written testimony framed the request around several priorities: Improving population health; Building reliable and actionable science; Broadening research portfolios to drive innovation; and, Accelerating discovery with next-generation tools. For Massachusetts, which is home to one of the densest concentrations of NIH-funded academic research in the country and the source of countless biotech spinouts, the proposed cut is substantial. Congress rejected the administration’s far more aggressive 40% cut last year on a bipartisan basis, and we’ll be watching closely to see whether appropriators take a similar approach this round.
SEC Proposes Sweeping Filer Status Reform: A Big Deal for Pre-Revenue Biotechs: On Monday, the SEC released a proposal that represents one of the most significant overhauls of public company regulatory framework in more than two decades. Among the most notable changes: the large accelerated filer threshold would move from $700M to $2B in public float, and, more importantly, companies would be able to maintain their existing filer status for a fixed 5-year window rather than being bumped up the moment their market cap crosses the threshold. For biotechs, this is especially meaningful. A single positive clinical readout can rapidly push a pre-revenue, cash-burning company’s market cap well past the old $700M ceiling, triggering the full weight of large-filer compliance costs that can run into the millions. Under the proposed reform, a biotech could ride a positive data event without immediately incurring those costs, and the new $2B threshold combined with the 60-month IPO on-ramp creates meaningful breathing room for emerging Massachusetts companies as they scale.
TrumpRx Expands to Include 600+ Generics: On Monday, President Trump announced a major expansion of TrumpRx.gov, adding more than 600 generic medications to the platform through partnerships with Mark Cuban’s Cost Plus Drugs, Amazon Pharmacy, and GoodRx. The platform, which launched in February to feature branded drugs covered by the administration’s Most-Favored-Nation pricing deals, now extends to widely used generics. The expansion significantly increases the platform’s drug offerings and signals the administration’s continued push to make direct-to-consumer pricing a defining feature of its drug pricing agenda. The broader questions remains: How does TrumpRx evolve from a vehicle for pharma pricing agreements into a framework that smaller, innovative companies will eventually be expected to participate in? While the pricing focus has remained on large pharma for now, the Administration has repeatedly signaled it is looking to make similar agreements with companies across the ecosystem.
Supreme Court Declines to Hear IRA Drug Pricing Challenges: Also on Monday, the U.S. Supreme Court declined to hear appeals from AstraZeneca, Bristol Myers Squibb, Novartis, Novo Nordisk, Boehringer Ingelheim, and Janssen challenging the Medicare Drug Price Negotiation Program established under the Inflation Reduction Act. The justices’ refusal to take up the cases leaves in place lower court rulings that rejected the manufacturers’ constitutional and statutory claims, effectively cementing the federal government’s authority to negotiate prices. For those developing small-molecule therapies subject to the IRA’s 9-year price negotiation timeline, the ruling reinforces the urgency of ongoing efforts to fix the small-molecule “pill penalty” and protect the economics that drive early-stage investment.
FDA Commissioner Search: Following Marty Makary’s resignation earlier this month, the White House is reportedly targeting sometime in June to announce a permanent successor, with Acting Commissioner Kyle Diamantas continuing to lead the agency in the interim. Senate HELP Committee Chair Bill Cassidy (R-LA) lost his bid for reelection in the Louisiana Republican Primary last week and has shared he plans to be more vocal on his areas of disagreement with the Administration, which may also complicate timing or viability of certain candidates the President nominates. There is therefore a real possibility the acting commissioner remains in place through year-end. The continued turnover at the top of the agency adds another layer of uncertainty to the already volatile regulatory environment at FDA.